Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants

Key facts

Sponsor

Meridigen Biotech Co., Ltd.

Intervention

Human Umbilical Cord Derived-Mesenchymal Stem Cells(biological)

Enrollment

9 enrolled

Eligibility

All sexes

Timeline

2018 – 2027

Study locations (1)

• National Chen-Kung University Hospital, Tainan, Taiwan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Bronchopulmonary dysplasia

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07109791
  National Surveillance and Prevention of Neonatal VAP
  University of Alberta
• RECRUITINGPHASE2NCT07561125
  Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below
  International Peace Maternity and Child Health Hospital
• RECRUITINGNANCT06373289
  Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
  University of Alabama at Birmingham
• RECRUITINGPHASE2NCT06915441
  Lipid Infusions to Optimize Nutrition Trial
  The University of Texas Health Science Center, Houston
• RECRUITINGPHASE1, PHASE2NCT07101640
  PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
  Duke University
• RECRUITINGNCT07273643
  Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality
  University Hospital, Montpellier
• RECRUITINGEARLY PHASE1NCT07120971
  Metformin for Premature Infants With Bronchopulmonary Dysplasia
  Medical College of Wisconsin
• RECRUITINGPHASE1NCT06589245
  Inhaled Ciclesonide Study in Preterm Infants
  Venkatesh Sampath

See all trials for Bronchopulmonary dysplasia →